Citations

Clear

3314 citation(s) found for "Yu, Alexander".

Abstract 2728: Cholecystokinin receptor antagonist proglumide reverses nonalcoholic steatohepatitis and prevents hepatocellular carcinoma
Gay, Martha D. , Ciofoaia, Victor, Nadella, Sandeep , Cao, Hong , Tucker, Robin D. , Shivapurkar, Narayan , Kroemer, Alexander , Huber, Matthew, Kallakury, Bhaskar , Smith, Jill Palmer

Mayo Clinic

Cancer Research | August 7, 2019 | Volume: 79 | Issue: 13_Supplement | Pages: 2728-2728

10.1158/1538-7445.am2019-2728 Get It

Abstract Background: The fastest growing cause of cancer related death is hepatocellular carcinoma (HCC), in part due to the rising prevalence of nonalcoholic steatohepatitis (NASH). HCC cases are expected to increase during 2015-2030. Cholecystokinin (CCK), blood levels are increased in those consuming high fat diets and CCK receptors have been identified in normal liver, fibroblasts, and immune cells. Hypothesis: We hypothesize that CCK receptor blockade could decrease NASH and prevent HCC in a mouse model.Methods: We examined whether CCK receptor blockade with proglumide could decrease NASH in the choline deficient ethionine supplemented (CDE)-diet mouse model. Two cohorts of Female C57BL/6 mice (N=65) mice were examined: (1) a preventive study in which mice were treated for 12 and 18 weeks to determine if proglumide could prevent NASH and HCC and (2) a ‘reversal study’ in which histologic and biochemical NASH was induced on a 75% CDE high fat diet for 12 weeks followed by treatment with proglumide for 6 weeks (until week 18) while remaining on the CDE diet to determine if CCK-receptor blockade could reverse NASH once established. Control mice received the same high fat diet with choline and half received proglumide therapy. Results: Alanine aminotransferase, aspartate aminotransferases, and bilirubin were increased in mice on the CDE/Regular (untreated water) diet and these values returned to near normal with proglumide therapy in the prevention study and also reversed after NASH was established. Histologic scoring showed significant decreased inflammation, fibrosis and steatosis in mice on the high fat CDE diet when treated with proglumide. 35% of the mice (N=23) at week 18 developed HCC or dysplastic nodules on the CDE diet while none of the mice in the CDE/proglumide prevention (N=15) or reversal therapy groups (N=15) had HCC. Mice on the lard-control diet had fatty livers at week 18 but no evidence of NASH histologically or biochemically and no HCC. Fibrosis was decreased in mice treated with proglumide as evidence by Masson’s trichrome stain and Western blot for FAP. Gene expression of the liver’s collagen-4, TGFβR11, PDGH-Rβ, and collagen-1α1 as determined by qRT-PCR decreased with proglumide treatment. Control diet fed mice had normal serum tests and fibrosis biomarkers. Conclusion: This data supports our novel hypothesis that CCK receptors play a role in NASH-associated HCC. CCK receptor blockade decreased histologic and biochemical evidence of NASH and prevented HCC. Since proglumide has already been tested in human subjects for peptic ulcer disease decades ago and is known to be orally bioavailable, results of our study could easily be translated into a clinical trial in human subjects to improve NASH to prevent HCC. Supported by AGA Research Foundation, Ruesch Foundation, and a grant from NIH, TL1TR001431 Citation Format: Martha D. Gay, Victor Ciofoaia, Sandeep Nadella, Hong Cao, Matthew Huber, Robin D. Tucker, Narayan Shivapurkar, Bhaskar Kallakury, Alexander H. Kroemer, Jill P. Smith. Cholecystokinin receptor antagonist proglumide reverses nonalcoholic steatohepatitis and prevents hepatocellular carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2728.
Brachial plexus nerve injury and repair in a rabbit model part II: Does middle trunk injury result in loss of biceps function while repair results in recovery of biceps function
Kollitz, Kathleen M. , Friedrich, Patricia F. , Bishop, Allen T., Shin, Alexander Y. , Shin, Alexander Y , Bishop, Allen T.

Mayo Clinic

Microsurgery | August 6, 2019 | Volume: 39 | Issue: 7 | Pages: 634-641

10.1002/micr.30500 | PMID 31386247 Get It

AbstractIntroductionThere is conflicting anatomic and innervation data regarding the rabbit brachial plexus injury model. This study aims to validate a rabbit brachial plexus injury model. We hypothesize the middle trunk (C6, C7) is the primary innervation of the biceps, and when cut and unrepaired, would demonstrate lack of recovery and when repaired would demonstrate evidence of recovery.Materials and MethodsTwenty two male New Zealand white rabbits (3–4 kg) underwent unilateral surgical division of the middle trunk. Five rabbits were randomly assigned to the “no‐repair” group while the remaining 17 rabbits underwent direct coaptation (“repair” group). Rabbits were followed for 12 weeks, with ultrasound measurement of biceps cross‐sectional area performed preoperatively, and at 4, 8, and 12 weeks postoperatively. At a euthanasia procedure, bilateral compound muscle action potential (CMAP) and isometric tetanic force (ITF) were measured. Bilateral biceps muscles were harvested and wet muscle weight was recorded. The operative side was expressed as a percentage of the non‐operated side, and differences between the no repair and repair rabbits were statistically compared.ResultsThe repair group demonstrated significantly higher CMA (23.3 vs. 0%, p < .05), ITF (25.6 vs. 0%, p < .05), and wet muscle weight (65.8 vs. 52.0%, p < .05) as compared to the unrepaired group. At 4 weeks postoperatively, ultrasound‐measured cross‐sectional area of the biceps demonstrated atrophy in both groups. At 12 weeks, the repair group had a significantly larger cross‐sectional area as compared to the no‐repair group (89.1 vs. 59.3%, p < .05).ConclusionsThis injury model demonstrated recovery with repair and lack of function without repair. Longer survival time is recommended for future investigations.
Immunotherapy in Hepatocellular Carcinoma: Is There a Light at the End of the Tunnel?
Mahipal, Amit , Tella, Sri Harsha , Kommalapati, Anuhya , Lim, Alexander, Mahipal, Amit , Kommalapati, Anuhya , Kim, Richard D.

Mayo Clinic

Cancers | July 30, 2019 | Volume: 11 | Issue: 8 | Pages: 1078

10.3390/cancers11081078 | PMID 31366113 Get It

Hepatocellular carcinoma (HCC) is the most common primary liver cancer with dismal prognosis when diagnosed at advanced stages. Surgical resection of the primary tumor or orthotropic liver transplantation serves as a potential curative option. However, this approach is highly dependent on the hepatic reserve and baseline functional status of the patient. Liver directed therapies such as portal vein embolization (PVE), trans-arterial chemoembolization (TACE), and systemic chemotherapy are employed in non-surgical candidates. Sorafenib was the only approved systemic therapeutic agent for almost a decade until the recent approval of lenvatinib by the United States Food and Drug Administration (FDA) as an alternate first-line agent. Regorafenib, nivolumab, pembrolizumab and cabozantinib are approved by the FDA as second-line agents in patients who failed or could not tolerate sorafenib. Ramucirumab was recently FDA approved for the subset of patients that have high alfa-fetoprotein levels (>400 ng/mL). A better understanding of tumorigenesis and encouraging clinical trial results that evaluated immune-checkpoint inhibitors opened doors for immunotherapy in HCC. Immune checkpoint inhibitors have demonstrated a prolonged median overall and progression-free survival in a subset of patients with HCC. On-going translational and clinical research will hopefully provide us with a better understanding of tumor markers, genetic aberrations and other factors that determine the immunotherapy response in HCC. In this review, we sought to summarize the potential role and future directions of immunotherapy in the management of HCC.
Patient Attitudes Toward Testicular Prosthesis Placement After Orchiectomy
Srivatsav, Ashwin , Balasubramanian, Adithya , Butaney, Mohit , Thirumavalavan, Nannan , McBride, J. Abram, Gondokusumo, Jabez, Lipshultz, Larry I. , Pastuszak, Alexander W.

Mayo Clinic

American Journal of Men's Health | July 30, 2019 | Volume: 13 | Issue: 4 | Pages: No page available

10.1177/1557988319861019 | PMID 31359823 Get It

Orchiectomy is the standard of care for many testicular conditions. Testicular prosthesis placement (TPP) can mitigate psychosocial burden, restore self-image, and improve quality of life for patients requiring orchiectomy. Limited data exist regarding patient attitudes and counseling on TPP in the United States. The objective of this study was to characterize patient experiences after TPP, rationale for pursuing/declining TPP, and satisfaction levels. Patients with a history of urologic conditions warranting orchiectomy were identified and sent an anonymous survey addressing demographics, pre/post counseling, attitudes toward TPP, satisfaction rates, and postoperative complications. Sixteen percent (76/480) of patients completed the survey. Of these, 50.8% (32/63) undergoing orchiectomy were counseled by their surgeon about TPP, and 22.2% (14/63) received a prosthesis. The most common reasons for declining TPP included lack of concern for cosmetic appearance and lack of counseling. Leading reasons for pursuing TPP included improving self-confidence and cosmetic appearance. Although 71% (10/14) of patients were satisfied with TPP, they did highlight areas for improvement. Twenty percent (2/10) felt their implant was too high, 60% (6/10) felt their implant was too firm, 10% (1/10) endorsed discomfort during sex, and 30% (3/10) felt that TPP did not match their size expectations. Despite these findings, 71% (10/14) reported that they would have TPP again and 79% (11/14) would recommend TPP to others. TPP improves body image and quality of life following orchiectomy. Provider counseling plays an important role in influencing a patient’s decision to undergo TPP. Areas of improvement include implant positioning and more effective replication of testicular consistency.
ACR guidance document on MR safe practices: Updates and critical information 2019
Greenberg, Todd D., Hoff, Michael N. , Gilk, Tobias , Och, Joseph, Rampulla, Tina L., Rogg, Jeffrey M. , Shellock, Frank G. , Watson, Robert E. , Weinreb, Jeffrey C. , Hernandez, Dina , Jackson, Edward F. , Kanal, Emanuel , McKinney, Alexander M. , Pedrosa, Iván , Reeder, Scott B.

Mayo Clinic

Journal of Magnetic Resonance Imaging | July 29, 2019 | Volume: 51 | Issue: 2 | Pages: 331-338

10.1002/jmri.26880 | PMID 31355502 Get It

The need for a guidance document on MR safe practices arose from a growing awareness of the MR environment's potential risks and adverse event reports involving patients, equipment, and personnel. Initially published in 2002, the American College of Radiology White Paper on MR Safety established de facto industry standards for safe and responsible practices in clinical and research MR environments. The most recent version addresses new sources of risk of adverse events, increases awareness of dynamic MR environments, and recommends that those responsible for MR medical director safety undergo annual MR safety training. With regular updates to these guidelines, the latest MR safety concerns can be accounted for to ensure a safer MR environment where dangers are minimized.Level of Evidence: 1Technical Efficacy Stage: 5J. Magn. Reson. Imaging 2020;51:331–338.
Guidelines for neuromuscular ultrasound training
Tawfik, Eman A. , Cartwright, Michael S. , Grimm, Alexander , Boon, Andrea J. , Kerasnoudis, Antonios , Preston, David C. , Wilder‐Smith, Einar , Axer, Hubertus , Hobson‐Webb, Lisa D., Crump, Nicholas , Shahrizaila, Nortina , Inkpen, Peter, Mandeville, Ross , Sakamuri, Sarada, Shook, Steven J. , Shin, Susan , Walker, Francis O. , Crump, Nicholas , Shin, Susan , Alfen, Nens van

Mayo Clinic

Muscle & Nerve | July 23, 2019 | Volume: 60 | Issue: 4 | Pages: 361-366

10.1002/mus.26642 | PMID 31335971 Get It

AbstractNeuromuscular ultrasound has become an essential tool in the diagnostic evaluation of various neuromuscular disorders, and, as such, there is growing interest in neuromuscular ultrasound training. Effective training is critical in mastering this modality. Our aim was to develop consensus‐based guidelines for neuromuscular ultrasound training courses. A total of 18 experts participated. Expert opinion was sought through the Delphi method using 4 consecutive electronic surveys. A high degree of consensus was achieved with regard to the general structure of neuromuscular ultrasound training; the categorization of training into basic, intermediate, and advanced levels; the learning objectives; and the curriculum for each level. In this study, a group of neuromuscular ultrasound experts established consensus‐based guidelines for neuromuscular ultrasound training. These guidelines can be used in the development of the specialty and the standardization of neuromuscular ultrasound training courses and workshops.
Mesothelioma: Scientific clues for prevention, diagnosis, and therapy
Carbone, Michele , Adusumilli, Prasad S. , Alexander, H. Richard , Baas, Paul, Bardelli, Fabrizio , Bononi, Angela , Bueno, Raphael , Felley‐Bosco, Emanuela , Galateau-Sallé, Françoise , Jablons, David M., Mansfield, Aaron S. , Minaai, Michael , Severson, David T. , Woodard, Gavitt A. , Yang, Haining , Pass, Harvey I. , Mansfield, Aaron S , Baas, Paul, de Perrot, Marc , Pesavento, Patricia A. , Rusch, Valerie W. , Taioli, Emanuela , Tsao, Anne S. , Zauderer, Marjorie G.

Mayo Clinic

CA: A Cancer Journal for Clinicians | July 8, 2019 | Volume: 69 | Issue: 5 | Pages: 402-429

10.3322/caac.21572 | PMID 31283845 Get It

Abstract Mesothelioma affects mostly older individuals who have been occupationally exposed to asbestos. The global mesothelioma incidence and mortality rates are unknown, because data are not available from developing countries that continue to use large amounts of asbestos. The incidence rate of mesothelioma has decreased in Australia, the United States, and Western Europe, where the use of asbestos was banned or strictly regulated in the 1970s and 1980s, demonstrating the value of these preventive measures. However, in these same countries, the overall number of deaths from mesothelioma has not decreased as the size of the population and the percentage of old people have increased. Moreover, hotspots of mesothelioma may occur when carcinogenic fibers that are present in the environment are disturbed as rural areas are being developed. Novel immunohistochemical and molecular markers have improved the accuracy of diagnosis; however, about 14% (high‐resource countries) to 50% (developing countries) of mesothelioma diagnoses are incorrect, resulting in inadequate treatment and complicating epidemiological studies. The discovery that germline BRCA1‐asssociated protein 1 ( BAP1 ) mutations cause mesothelioma and other cancers (BAP1 cancer syndrome) elucidated some of the key pathogenic mechanisms, and treatments targeting these molecular mechanisms and/or modulating the immune response are being tested. The role of surgery in pleural mesothelioma is controversial as it is difficult to predict who will benefit from aggressive management, even when local therapies are added to existing or novel systemic treatments. Treatment outcomes are improving, however, for peritoneal mesothelioma. Multidisciplinary international collaboration will be necessary to improve prevention, early detection, and treatment.
Multidetector CT Findings in the Abdomen and Pelvis after Damage Control Surgery for Acute Traumatic Injuries
Alexander, Lauren F. , LeGout, Jordan D. , Roda, Manohar, Cernigliaro, Joseph G. , Harri, Peter A., Hanna, Tarek N, Roda, Manohar S, Mittal, Pardeep K, Alexander, Lauren F , Hanna, Tarek N , Mittal, Pardeep Kumar

Mayo Clinic

RadioGraphics | July 8, 2019 | Volume: 39 | Issue: 4 | Pages: 1183-1202

10.1148/rg.2019180153 | PMID 31283454 Get It

The rabbit brachial plexus as a model for nerve injury and repair Part 1: Anatomic study of the biceps and triceps innervation
Kollitz, Kathleen M. , Giusti, Guilherme , Friedrich, Patricia F. , Shin, Alexander Y. , Shin, Alexander Y , Bishop, Allen T.

Mayo Clinic

Microsurgery | June 27, 2019 | Volume: 40 | Issue: 2 | Pages: 183-188

10.1002/micr.30482 | PMID 31246325 Get It

AbstractPurposeAnimal models can be helpful in evaluating new surgical strategies for brachial plexus reconstruction. While several groups have already used the rabbit brachial plexus to model injury, reports conflict in anatomic detail and do not identify a nerve‐muscle pair to measure motor function recovery after reconstruction. The purpose of the current study is to describe the innervations of the biceps and triceps muscles in rabbits, which are both amenable to study in brachial plexus injury models.Materials and MethodsThirteen rabbits weighing 2–2.5 kg were anesthetized. Six rabbits were sacrificed and dissected using loupe and microscope magnification to understand the overall morphology of the brachial plexus. Seven rabbits underwent electrophysiologic investigation. A bipolar nerve stimulator was used to systematically stimulate the roots, trunks and divisions, and nerve branches of the rabbit brachial plexus and compound muscle action potential was used to record muscle response. Nerve length and width measurements were not recorded.ResultsRoots contributing to the brachial plexus were C5, C6, C7, C8, and T1. In contrast to other anatomical studies, T2 did not contribute to the brachial plexus. The triceps was innervated by the radial nerve, which received contributions from C6 (1.6 mA), C7 (1.9 mA), C8, and T1 (12.2 mA).The biceps had dual innervation (proximally and distally). The proximal branch received contributions from C6 (3.5 mA) and C7 (5mA). The distal portion was innervated by a branch from the median nerve, which received innervation from C6, C7, C8, and T1.ConclusionsThe overall structure of rabbit brachial plexus is described and innervation of the biceps and triceps is described in detail. This anatomic investigation will form the basis of a future brachial plexus model of injury and repair.
Myoglobinuria in Autopsy Pathology: Relevant and Potentially Unrecognized
Blessing, Melissa M. , Reichard, R. Ross , Maleszewski, Joseph J. , Alexander, Mariam P.

Mayo Clinic

Academic Forensic Pathology | June 26, 2019 | Volume: 4 | Issue: 2 | Pages: 226-234

10.23907/2014.035 Get It

Background Myoglobin-related renal injury (MRRI) is a significant cause of acute renal injury and may result in death. Common etiologies in forensic pathology include trauma and drug abuse. This study sought to determine the prevalence and causes of MRRI at autopsy and discuss diagnostic challenges. Methods The institutional autopsy archives were queried for cases in which a myoglobin (MG) immunohistochemical stain was performed or MRRI was diagnosed or considered. The clinicopathological characteristics of this population were described. Results Of 9996 cases over a period of 19.5 years, 17 cases (0.2%) fulfilled the criteria. Patient age ranged from 15 to 74 years; 11 were men. The MG stain was performed in 13 cases. In 11 (65%) cases, MRRI was diagnosed with or without immunohistochemistry. The clinical backgrounds were varied; sepsis and liver injury predominated. Time between original insult and death ranged from seven hours to four months. Patterns of MRRI included cast formation or fine brush border staining in the proximal tubules. Discussion MRRI is infrequently considered in the autopsy setting. Many causes of MRRI identified in this series involved circumstances placing the death into medical examiner jurisdiction; the MG stain contributed to understanding the mechanism of death. Acute tubular injury with cast formation was observed in the majority of cases. Conclusion MRRI is common in a select group of autopsies but may be underappreciated. The MG stain is a useful and inexpensive tool to aid in the diagnosis of MRRI in autopsy pathology.